You are here
CERID Bibliography
Export 27 results:
Author Title [ Type] Year Filters: Keyword is Animals and Author is Verlinde, Christophe L M J [Clear All Filters]
2-Oxo-tetrahydro-1,8-naphthyridines as selective inhibitors of malarial protein farnesyltransferase and as anti-malarials. Bioorg Med Chem Lett. 2008 ;18(2):494-7.
. 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. J Med Chem. 2008 ;51(3):384-7.
. Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands. J Biomol Screen. 2009 ;14(6):700-7.
Characterization of Trypanosoma brucei dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies. Mol Microbiol. 2008 ;68(1):37-50.
Cloning and analysis of Trypanosoma cruzi lanosterol 14alpha-demethylase. Mol Biochem Parasitol. 2003 ;132(2):75-81.
. Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 A resolution reveals intriguing extra electron density in the active site. Proteins. 2006 ;62(3):570-7.
Crystal structure of the aspartyl-tRNA synthetase from Entamoeba histolytica. Mol Biochem Parasitol. 2010 ;169(2):95-100.
Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. J Mol Biol. 2010 ;397(2):481-94.
Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother. 2007 ;51(10):3659-71.
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov. 2008 ;7(11):900-7.
Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother. 2008 ;52(10):3710-7.
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib. Antimicrob Agents Chemother. 2012 ;56(9):4914-21.
The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease. J Med Chem. 2005 ;48(17):5415-8.
. Rational modification of a candidate cancer drug for use against Chagas disease. J Med Chem. 2009 ;52(6):1639-47.
. Resistance mutations at the lipid substrate binding site of Plasmodium falciparum protein farnesyltransferase. Mol Biochem Parasitol. 2007 ;152(1):66-71.
. Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. J Biol Chem. 2005 ;280(14):13554-9.
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. J Med Chem. 2010 ;53(10):3887-98.
. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem. 2007 ;50(19):4585-605.
Selective inhibitors of methionyl-tRNA synthetase have potent activity against Trypanosoma brucei Infection in Mice. Antimicrob Agents Chemother. 2011 ;55(5):1982-9.
Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. Angew Chem Int Ed Engl. 2005 ;44(31):4903-6.
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease. J Med Chem. 2009 ;52(12):3703-15.
Structure of ribose 5-phosphate isomerase from Plasmodium falciparum. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 ;62(Pt 5):427-31.
Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity. J Mol Biol. 2008 ;381(4):975-88.
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nat Struct Mol Biol. 2010 ;17(5):602-7.
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest. 2012 ;122(6):2301-5.